Klotho Neurosciences (KLTO) Bolsters Advisory Board with Biotech Powerhouse Dr. Robert Langer, Co-Founder of Moderna

Biotech Pioneer to Drive Klotho’s Pipeline in Neuroscience and Therapeutic Development

Strategic Expansion Targeting Multi-Billion-Dollar Markets with Patented Klotho Gene Technology

Klotho Neurosciences, Inc. (Nasdaq: KLTO), a leader in developing therapies for neurodegenerative diseases and promoting healthy longevity, announced a pivotal milestone: Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board.

Dr. Langer is an MIT professor and one of the most cited researchers in history. His pioneering work in drug delivery systems and tissue engineering has earned him numerous accolades, including the National Medal of Science. As a co-founder of Moderna, he played a pivotal role in developing mRNA-based therapeutics, including the groundbreaking COVID-19 vaccine. His involvement with Klotho Neurosciences underscores his confidence in the company’s mission to address unmet medical needs in ALS, Alzheimer’s and Parkinson’s diseases.

Dr. Langer commented, “I am excited to collaborate with the team at Klotho Neurosciences as they explore the therapeutic potential of the Klotho protein in combating neurodegenerative conditions. The company is working on something incredibly promising, and I’m eager to support their efforts.”

Klotho Neurosciences is strategically advancing its focus on neurodegenerative diseases and healthy aging. Its primary candidate targets ALS, with the global ALS market valued at $667.3 million and growing. Additionally, Klotho is developing therapies for Alzheimer’s and Parkinson’s using its proprietary s-KL gene therapy platform. The global Alzheimer’s therapeutics market was valued at $4.05 billion in 2022 and is expected to grow at a CAGR of 19.99% from 2023 to 2030. Collaborating with “Blue Zone” researchers, Klotho aims to identify biomarkers for healthy aging and develop early detection methods to enhance patient outcomes.

 

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc., formerly ANEW MEDICAL, INC., is a Nasdaq-listed pharmaceutical company with the ticker symbol KLTO. The company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and know-how to develop cutting-edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s disease, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in medical product development and commercialization of medical products. For additional information, please visit www.klothoneuro.com.

Share this article:

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

Share This Article

 

About the Author

Klotho Neurosciences (KLTO) Bolsters Advisory Board with Biotech Powerhouse Dr. Robert Langer, Co-Founder of Moderna

Ashlee Vogenthaler

Markets Editor